Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer (NCT01368588)

🧪 Interventions in This Study

• Anti-androgen (DRUG)
• luteinizing hormone-releasing hormone (LHRH) agonist or antagonist (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (478 Sites)

Showing the first 25 of 478 sites.

• University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
• Anchorage Associates in Radiation Medicine — Anchorage, Alaska
• Alaska Oncology and Hematology LLC — Anchorage, Alaska
• Anchorage Oncology Centre — Anchorage, Alaska
• Katmai Oncology Group — Anchorage, Alaska
• Providence Alaska Medical Center — Anchorage, Alaska
• Fairbanks Memorial Hospital — Fairbanks, Alaska
• Arizona Breast Cancer Specialists-Gilbert — Gilbert, Arizona
• Arizona Center for Cancer Care-Peoria — Peoria, Arizona
• Cancer Center at Saint Joseph's — Phoenix, Arizona
• Saint Joseph's Hospital and Medical Center — Phoenix, Arizona
• Arizona Breast Cancer Specialists-Phoenix — Phoenix, Arizona
• Arizona Oncology-Deer Valley Center — Phoenix, Arizona
• 21st Century Oncology-Scottsdale — Scottsdale, Arizona
• Arizona Breast Cancer Specialists — Scottsdale, Arizona
• Arizona Breast Cancer Specialists-Scottsdale — Scottsdale, Arizona
• Arizona Oncology Services Foundation — Scottsdale, Arizona
• Arizona Center for Cancer Care-Surprise — Surprise, Arizona
• Arizona Oncology Associates-West Orange Grove — Tucson, Arizona
• University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
• Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
• University of Arkansas for Medical Sciences — Little Rock, Arkansas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Cancer

• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
• A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
• Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
• A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
• Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland

Explore by condition: All Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.